CTMX
CytomX Therapeutics·NASDAQ
--
--(--)
--
--(--)
7.43 / 10
Outperform
Analyst consensus is bullish: 50% Strong Buy and 50% Buy from eight recent ratings, with several analysts showing high historical win rates. Fund‑flow metrics are positive (score 7.9), inflow ratios above 0.5 across all size bands, reinforcing optimism.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
50%
Buy
50%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-03-16
InstitutionJP Morgan
Times predicted1
Historical Win Rate0.0%
What is the market sentiment for CTMX?
- CTMX holds a Bullish analyst rating, with 50% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 7.43/10 (Outperform).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
